The Nantz National Alzheimer Center at Houston Methodist Hospital is part of a landmark clinical trial that looks at removing a key protein from the brain to prevent memory loss at least a decade before symptoms are noticed in healthy older adults.
The national trial is focused on an investigational treatment to reduce the impact of the protein beta amyloid. The A4 study, also known as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study, is for individuals ages 65 to 85 who are deemed at risk for Alzheimer’s disease related memory loss, but who have not yet shown signs of the disease.
Using positron emission tomography (PET scans), researchers and clinicians have found that beta amyloid begins forming plaques in the brains of people with Alzheimer’s disease 10-20 years before the initial symptoms of the disease. Scientists believe the accumulation of beta amyloid may play a key role in the eventual development of Alzheimer’s-related memory loss, by inducing excess production of an abnormal form of the important brain protein, tau.
The investigational drug used in the A4 study is the mono-clonal antibody solanezumab, which targets excess amyloid in the brain. The goal of this study is to learn whether solanezumab will delay cognitive decline and memory loss symptoms in patients who have not yet been diagnosed by slowing possible Alzheimer’s related damage in the brain.
Joseph Masdeu, M.D., and his team at the Nantz National Alzheimer Center in Houston is one of a handful of study sites to also scan patients for abnormal tau, which forms tangles of fibers that likely destroy nerve cells and spread brain damage.
“It is encouraging to be able to detect excess beta amyloid with PET technology in people predisposed to Alzheimer’s and then try to lower the amyloid levels with solanezumab,” said Masdeu, principal investigator of the A4 study at Houston Methodist Hospital and director of the Nantz National Alzheimer Center. “However, there appears to be a point in the development of Alzheimer’s where removing beta amyloid does not reverse or stop disease progression because too much abnormal tau has been generated by then. That is why it is important to use PET to measure the amount of abnormal brain tau as well.”
Masdeu was the first physician-scientist to detect an early imaging feature of Alzheimer’s disease and has long focused on neuroimaging’s role in determining the brain changes that underlie the memory and language problems characteristic of Alzheimer’s disease.
According to the Alzheimer’s Association, someone in the United States develops Alzheimer’s every 67 seconds and 16 million Americans are expected to be affected by the disease by 2050. In 2014, Alzheimer’s caregivers provided an estimated 17.9 billion hours of unpaid care valued at more than $217.7 billion.
“Among the major causes of death in the United States, Alzheimer’s is the only one that we currently cannot prevent or cure,” said Masdeu. “We hope that slowing the onset of Alzheimer’s will help patients hold on until a prevention or cure can be found.”
To qualify for the study, patients must be between the ages 65 and 85 and have a study partner who is willing to participate as a source of information and has at least weekly contact with the participant. Neuroimaging testing using a PET scan will determine whether abnormal beta amyloid deposits are present in the brain. If so, study patients will be randomized to either the investigational treatment or a placebo group.
Approximately 1,000 adults are expected to participate in more than 60 sites across the United States, Canada and Australia. Masdeu expects to enroll 30 people at Houston Methodist Hospital. The three-year study is funded by the National Institute on Aging, Eli Lilly and Company, and several philanthropic organizations. The A4 study is coordinated by the Alzheimer’s Disease Cooperative Study.
The Latest on: Anti-Amyloid Treatment
[google_news title=”” keyword=”Anti-Amyloid Treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-Amyloid Treatment
- Eisai: "LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japanon September 25, 2023 at 5:00 pm
"Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early ...
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in ...on September 25, 2023 at 2:36 pm
“Across many trials of anti-amyloid treatments, p-tau 181 has emerged as a consistent plasma biomarker that appears to correlate with clinical benefit. Upon analysis of the plasma p-tau 181 data ...
- "LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japanon September 25, 2023 at 11:46 am
“Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the ...
- Leqembi approved in Japan, its first ex-US marketon September 25, 2023 at 12:58 am
The Japanese approval comes a few weeks after Leqembi was granted full approval by the FDA in the US, having been awarded conditional approval at the start of 2023. A similar requirement for a ...
- LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japanon September 25, 2023 at 12:02 am
Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI ® Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan ...
- ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’son September 22, 2023 at 12:02 pm
Two years of oral ALZ-801 sustained cognition and lower levels of disease-related biomarkers in early Alzheimer’s patients with APOE4 variant ...
- Will there ever be a cure for Alzheimer’s disease?on September 21, 2023 at 2:00 am
As the population ages, Alzheimer’s disease is more prevalent. Will treatment ever be effective enough or will prevention be key?
- People with Down syndrome deserve access to Alzheimer’s treatmenton September 20, 2023 at 11:03 am
People with Down syndrome helped scientists pave the way for Alzheimer’s drugs but are now left out of the treatment.
- Nasal Alzheimer’s drug effective regardless of brain plaque levelson September 18, 2023 at 12:03 am
Researchers have found that an intranasal immunotherapy drug, currently being tested as a treatment for multiple sclerosis, reduced brain inflammation and improved cognition in mice with Alzheimer’s ...
- Moving Beyond Anti-amyloid Therapy for the Prevention and Treatment of Alzheimer's Diseaseon September 10, 2023 at 5:00 pm
Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies. Discussion These therapies are based ...
via Bing News